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Abstract
Introduction:  Baroreﬂex  function  is an  independent  marker  of  prognosis  in heart  failure  (HF).
However, little  is known  about  its relation  to  response  to  cardiac  resynchronization  therapy
(CRT).  The  aim  of  this  study  is to  assess  arterial  baroreﬂex  function  in  HF  patients  who  are
candidates  for  CRT.
Methods: The  study  population  consisted  of  25  patients  with  indication  for  CRT,  aged  65±10
years, NYHA  functional  class  ≥III  in  52%,  QRS  width  159±15  ms,  left  ventricular  ejection  frac-
tion  (LVEF)  29±5%,  left  ventricular  end-systolic  volume  (LVESV)  150±48  ml,  B-type  natriuretic
peptide  (BNP)  357±270  pg/ml,  and  peak  oxygen  consumption  (peak  VO2) 18.4±5.0  ml/kg/min.
An  orthostatic  tilt  test  was  performed  to  assess  the  baroreﬂex  effectiveness  index  (BEI)  by  the
sequence  method.  This  group  was  compared  with  15  age-matched  healthy  individuals.
Results: HF  patients  showed  a  signiﬁcantly  depressed  BEI  during  tilt  (31±12%  vs.  49±18%,
p=0.001). A lower BEI  was  associated  with  higher  BNP  (p=0.038),  lower  peak  VO2 (p=0.048),
and  higher  LVESV  (p=0.031).  By  applying  a  cut-off  value  of  25%  for  BEI,  two  clusters  of  patients
were  identiﬁed:  lower  risk cluster  (BEI  >25%)  QRS  153  ms, LVESV  129  ml,  BNP  146  pg/ml,
peak  VO2 19.0  ml/kg/min;  and higher  risk  cluster  (IEB  ≤25%)  QRS  167  ms,  LVESV  189 ml,  BNP
590  pg/ml,  peak  VO2 16.2  ml/kg/min.
Conclusions:  Candidates  for  CRT  show  depressed  arterial  baroreﬂex  function.  Lower  BEI  was
observed in high-risk  HF patients.  Baroreﬂex  function  correlated  closely  with  other  clinical  HF
parameters.  Therefore,  BEI  may  improve  risk  stratiﬁcation  in HF patients  undergoing  CRT.
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PALAVRAS-CHAVE
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arterial
O índice  de eﬁcácia  do barorreﬂexo  na  estratiﬁcac¸ão  de  risco  de  doentes  com
insuﬁciência  cardíaca  crónica  candidatos  à terapêutica  de  ressincronizac¸ão  cardíaca
Resumo
Introduc¸ão:  O  barorreﬂexo  arterial  é comprovadamente  um  marcador  independente  de
prognóstico na  IC.  Contudo,  pouco  se  sabe  sobre  a  relac¸ão  entre  a  func¸ão  do  barorreﬂexo  e
a  resposta  à  TRC.  Assim,  o  objetivo  deste  estudo  é avaliar  a  func¸ão  barorreﬂexa  em  doentes
com  IC  candidatos  a  TRC.
Métodos: A populac¸ão  deste  estudo  prospetivo  consistiu  em  25  doentes  com  65±10  anos,  classe
NYHA ≥III  em  52%,  QRS 159±15  ms,  frac¸ão  de  ejec¸ão  do  ventrículo  esquerdo  (FEVE)  29±5%,  vol-
ume  telessistólico  do ventrículo  esquerdo  (VTSVE)  150±48  mL,  péptido  natriurético  tipo-B  (BNP)
357±270  pg/ml,  consumo  máximo  de oxigénio  (VO2  max)  18,4±5,0  ml/kg/min.  Foi  implemen-
tado um  teste  de  ortostatismo  passivo  para  avaliar  o índice  de  eﬁcácia  do  barorreﬂexo  (IEB),
através  do  método  sequencial.  O  grupo controlo  foi constituído  por 15  indivíduos  saudáveis
emparelhados  para  a  idade.
Resultados: Os  doentes  com  IC  apresentaram  um IEB signiﬁcativamente  reduzido  durante  o  tilt
(31±12%  versus  49±18%,  p=0,001).  Um  IEB  diminuído  associou-se  a  um  BNP  elevado  (p=0,038),
a  um  VO2  diminuído  (p=0,048)  e a  um VTSVE  aumentado  (p=0,031).  Aplicando  um  cut-off  25%
para  o IEB,  foram  identiﬁcados  dois  clusters  de doentes:  cluster  de risco  menor  risco  (IEB>25%)
QRS  153  ms,  VTSVE  129 mL,  BNP 146 pg/mL,  VO2  max  19,0  mL/kg/min;  cluster  de  maior  risco
(IEB≤25%)  QRS  167  ms,  VTSVE  189  mL,  BNP  590  pg/mL,  VO2  max  16,2  mL/kg/min.
Conclusões:  Doentes  candidatos  a  TRC  apresentam  barorreﬂexo  deprimido.  O  BEI  diminuído
foi observado  nos  doentes  de  maior  risco.  O  barorreﬂexo  correlacionou-se  bem  com  outros
parâmetros  de  gravidade  de  IC.  Desta  forma,  o  BEI pode  contribuir  para  a  estratiﬁcac¸ão  de
risco  dos  doentes  com  IC  submetidos  a  TRC.
©  2016  Sociedade  Portuguesa  de Cardiologia.  Publicado  por  Elsevier  Espan˜a,  S.L.U.  Todos  os
direitos  reservados.
List  of  abbreviations
ACE angiotensin-converting  enzyme
ANS autonomic  nervous  system
BEI baroreﬂex  effectiveness  index
BNP brain-type  natriuretic  peptide
BP blood  pressure
CRT cardiac  resynchronization  therapy
HF heart  failure
HR heart  rate
HRV heart  rate  variability
LBBB left bundle  branch  block
LV left ventricular
LVEDV  left ventricular  end-diastolic  volume
LVEF left ventricular  ejection  fraction
LVESV left ventricular  end-systolic  volume
NBR number  of  baroreﬂex  events  per  minute
NYHA New  York  Heart  Association
RR R-R  interval  on  electrocardiogram
SBP systolic  blood  pressure
VO2 oxygen  consumption
Introduction
Chronic  heart  failure  (HF)  is  a clinical  syndrome  that  affects
millions of  people  worldwide1 and  is  responsible  for high
mortality  and  morbidity  and  decreased  quality  of life.2
Although  HF affects  1% of  the  adult  population,  its preva-
lence reaches  6-10%  of  people  over  the age of 65  years1
and it  is  responsible  for  at least  20%  of  all  hospital  admis-
sions among  the  elderly.3 Nearly  30%  of  patients  with  HF
with decreased  ejection  fraction  also  present  left  ventricu-
lar (LV)  electrical  dyssynchrony  that results  in  a  QRS  interval
greater than  120  ms,  most commonly  with  a left bundle
branch block  (LBBB)  pattern.4 LV  electrical  dyssynchrony
results in  decreased  diastolic time,  anomalous  septal  motion
and increased  mitral  regurgitation,  with  an overall  reduction
in left  ventricular  ejection  fraction  (LVEF).1,5
Cardiac  resynchronization  therapy  (CRT)  has  shown
important clinical  beneﬁts  in the  treatment  of  HF  patients
with systolic  dysfunction  (LVEF  <35%)  and electrical  dyssyn-
chrony (QRS  >120  ms).4,6 By  reducing  ventricular  electrical
dyssynchrony,  CRT  improves  LV systolic  function  while
reducing myocardial  oxygen consumption,7 which  results
in improvement  of  symptoms  and quality  of  life  and  in a
signiﬁcant reduction  in mortality.4,8,9 However,  up  to  30%
of patients  do not  respond  to  CRT (nonresponders).10--12
CRT responders  undergo  LV reverse  remodeling,  which
is characterized  by  decreases  in intraventricular  conduc-
tion delay  and  LV  end-systolic  volume  (LVESV)  and
reduction in  mitral  regurgitation  area, with  a  consequent
increase in LVEF.8,12,13 LV  reverse  remodeling  is  thought  to
be responsible  for the  clinical  improvement  in responders
to CRT,  but  the  mechanisms  underlying  reverse  remodeling
are not  well  understood.
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The  autonomic  nervous  system  (ANS)  may  play  an
important role  in reverse  remodeling.  The  ANS  has
an important  role  in cardiovascular  functional  and  struc-
tural regulation,14,15 but  ANS  function  is  also  recognized  as
a prognostic  marker  in HF.16 Furthermore,  CRT  induces  a
reduction in  mean  heart  rate  (HR)  and  an  increase  in heart
rate variability  (HRV).17--19 Najem  et al. also  showed  that
there was  an  acute  increase  in cardiac  sympathetic  activity
after biventricular  pacing  was  switched  off.20 More  recently,
an improvement  in cardiac  sympathetic  activity  has  been
demonstrated in responders  to  CRT,  assessed  by 123I-MIBG
scintigraphy.21,22
Nevertheless,  little  is known  of the impact  of  CRT  on
arterial baroreﬂex  function.  The  arterial  baroreﬂex  (with
afferents from  aortic  and  carotid  baroreceptors)  is  crucial
in the  homeostatic  regulation  of  blood  pressure  (BP).23 It
is also  a  well-established  independent  prognostic  marker  in
HF; there  is  evidence  that low baroreﬂex  sensitivity  is  asso-
ciated with  increased  cardiovascular  morbidity  and  overall
mortality.24 However,  it is  not known  whether  baroreﬂex
function before  CRT  correlates  with  severity  of  HF or  with
the response  to  cardiac  resynchronization.  Therefore,  the
aim of  the  present  study  was  to  assess  baroreﬂex  function  in
HF patients  who  were candidates  for  CRT,  and  to  compare  it
with other  clinical  and  laboratory  parameters  of  HF  severity.
Methods
Population
Patients  of  both  sexes  with  class  I recommendation  for
CRT were  included.  We  thus  included  patients  in  sinus
rhythm with  symptomatic  HF refractory  to  optimal  medical
treatment, in  New  York  Heart  Association  (NYHA)  functional
class II  or  III  or  outpatients  in class  IV, with  LVEF  <35%
and QRS  width  >120  ms.6 Patients  in NYHA  class  II  with
wider QRS  and  lower  LVEF  (QRS  >130  ms  and LVEF  <30%)
were included.6,13 Patients  with  atrial  ﬁbrillation/ﬂutter,
second or  third  degree  atrioventricular  block  or  frequent
supraventricular or  ventricular  ectopic  beats, and  those
with a  pacing  rhythm  were  excluded  from  this study,  as
sinus rhythm  is  a  prerequisite  for  reliable  arterial  baroreﬂex
measurement.25 Patients  were  recruited  at the Cardiology
Department of  Santa  Marta  Hospital.  All  patients  provided
written informed  consent  according  to  the  principles  of  the
Helsinki Declaration.
Protocol
This  was  an  exploratory  clinical  study.  Before  CRT  implan-
tation, all  patients  underwent  clinical  assessment  including
NYHA functional  class,  laboratory  testing  including  deter-
mination of brain-type  natriuretic  peptide  (BNP),  a 12-lead
electrocardiogram (ECG)  (Philips  TRIM  III),  transthoracic
echocardiogram and cardiopulmonary  exercise  test  (CPET).
An orthostatic  tilt  test  was  used  to  study  baroreﬂex  function.
Transthoracic echocardiography
Transthoracic echocardiographic  images  were  obtained
using Vivid  7 equipment  (General  Electric-Vingmed,  Milwau-
kee, WI).  The  echocardiographic  assessment  was performed
in  M-mode,  biplane  and  Doppler  modes.  LVEF,  LVESV  and
LV end-diastolic  volume  (LVEDV)  were  determined  using
Simpson’s  biplane  method.26,27 A  semi-quantitative  Doppler
method was  used to  assess  mitral  regurgitation  grade.
Cardiopulmonary  exercise  test
Patients were  instructed  to  avoid  any  intense  physical  acti-
vity and  not  to  smoke  or  ingest  any caffeine-containing
drinks  in the  three  hours  preceding  the  exam.  CPET  was
performed on  a treadmill  according  to  the modiﬁed  Bruce
protocol.28 Patients  exercised  until  maximal  fatigue  was
reached.29 During  the test  an ECG  and  a respiratory  mass
spectrometer with  capnography  were used to  continuously
monitor HR,  ventilation,  oxygen  consumption  and carbon
dioxide production.  Using  these,  peak  HR  and  peak oxygen
consumption (peak VO2)  were determined.
Orthostatic tilt  test  and  baroreﬂex  function  assessment
Tilt  test  protocol.  Orthostatic  tilt  testing  was  performed  in
a temperature-controlled  autonomic  function  lab.  Patients
were instructed  to  avoid  any kind  of intense  physical  acti-
vity before  the test  and  to  avoid  smoking  or  drinking  any
caffeine-containing drinks  in the three  hours  preceding  the
exam. No  peripheral  venous  catheters  were  used and  no
drugs were  administered  during  the entire  exam.  All sub-
jects underwent  a  10-min  basal  resting  period  in the supine
position, or slightly  inclined  in accordance  with  individual
sleeping habits  to  prevent  respiratory  discomfort.25 Sub-
jects were  tilted  up  to  70◦ using  a passive  electronic  tilt
table. The  orthostatic  period  was  maintained  for 10  min,
after which  subjects  returned  to their  basal  inclination  for
a 10-min  recovery  period.30,31
Data  acquisition  and  analysis.  ECG  and  peripheral  BP were
continuously and noninvasively  recorded  during  the tilt  test
(Task Force  Monitor,  CNSystems,  Graz, Austria).  Hemody-
namic data  were  then  analyzed  using  software  developed  in
our lab  (FisioSinal32). This  system  uses  an algorithm  to detect
systolic blood  pressure  (SBP)  peaks  and  R-wave  peaks  in each
QRS complex  of the ECG  from  which  the RR  interval  can be
calculated. In  this  way,  signals  depicting  the evolution  of
SBP over  time  (systogram)  and RR  interval  (tachogram)  were
reconstructed.33,34 The  reconstructed  signals  were  used  to
calculate the baroreﬂex  effectiveness  index  (BEI).
Baroreﬂex  effectiveness  index  measurement.  To  assess
arterial baroreﬂex  function,  the BEI  was  calculated  by
the sequence  method.35,36 Brieﬂy,  the BEI is  calculated
on the basis  of  beat-to-beat  analysis  of cardiovascular
signals. The  algorithm  identiﬁes  SBP  ramps  of three  or
more consecutive  beats  characterized  by  a progressive
increase (up-ramp)  or  decrease  (down-ramp)  of at  least
1 mmHg.  Spontaneous  baroreﬂex  sequences  (baroreﬂex
events) were  deﬁned  as  SBP  ramps  followed  by  concomitant
and concordant  lengthening  or  shortening  of  RR  inter-
vals of  at least 5  ms.  The  RR  intervals  were scanned
with a lag  from  the  SBP  ramp  of  0, 1  or  2 beats, each
sequence being  included  only once.36 Baroreﬂex  events
were only considered  reliable  when  there  was  a strong  cor-
relation between  SBP  ramps  and concomitant  RR-interval
ramps (correlation  coefﬁcient  >0.835).  The  total  number
of baroreﬂex  events  per  minute  (NBR)  of  the  analysis
was calculated,  as  well  as  the BEI, which  is  deﬁned  as
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the  ratio  between  baroreﬂex  events  and  the total  num-
ber of  SBP  ramps.  The  higher  the  BEI, the greater  the
effectiveness of  the arterial  baroreﬂex  in  hemodynamic
adaptation to  changes  in blood  pressure.36,37
As  assessment  of  baroreﬂex  function  is  ideally  per-
formed under  stationary  conditions,37 baroreﬂex  analysis
was divided  into  three  periods  for  each  patient:
1) Basal:  5  min  of  basal  period  in supine  position;
2) Tilt:  10  min  at 70◦ orthostatic  position;
3)  Recovery:  5 min  of  recovery  in basal  supine  position.
Statistical analysis
The  statistical  analysis  was  performed  in SPSS  software  (ver-
sion 20,  IBM,  USA).  Categorical  variables  were  expressed
as percentages  or  frequencies  and  continuous  variables  as
means ±  standard  deviation.  The  Kolmogorov-Smirnov  test
was used  to  test  the normal  distribution  of continuous
variables.  The  non-parametric  Mann-Whitney  test  was  used
to compare  groups.  Pearson’s  correlation  coefﬁcient  was
applied to test  the correlation  between  BEI  and  the other
continuous variables  used to describe  HF  severity.  The  divi-
sion of  patients  according  to  HF  severity  was  performed  by
k-means clustering.  A  p value  <0.05  was  considered  statisti-
cally signiﬁcant.
Results
Population
In this  study,  25  HF  patients  with  a mean  age of  65±10
years were  included,  of  whom  20%  were female.  Table  1
summarizes the patients’  demographic  and  clinical  char-
acteristics. In  approximately  half  of the  population  (13
patients, 52%)  ischemic  cardiomyopathy  was  the  etiology
of HF,  the  remaining  12  (48%)  patients  having  HF  of  other
causes. In  total,  11  patients  were  in NYHA  functional  class
Table  1  Clinical  characteristics  of  heart  failure  patients
who were  candidates  for  cardiac  resynchronization  therapy.
n  25
Female  5 (20%)
Age  (years)  65±10
HF  etiology
Ischemic  13  (52%)
Non-ischemic  12  (48%)
NYHA  class  II/III/IV  11/13/1
QRS  duration  (ms)  159±15
LVEF  (%)  29±5
LVESV  (ml) 150±48
LVEDV  (ml)  207±60
Peak  VO2 (ml/kg/min) 18.4±5.0
BNP  (pg/ml) 357±250
BNP: brain-type natriuretic peptide; HF:  heart failure; LVEDV:
left  ventricular end-diastolic volume; LVEF: left ventricular ejec-
tion  fraction; LVESV: left ventricular end-systolic volume; NYHA:
New  York Heart Association; VO2: oxygen consumption.
Table  2 Comorbidities  and  pharmacologic  treatment.
Comorbidities
Hypertension  88%
Dyslipidemia  80%
Diabetes  32%
Obesity  28%
Chronic  kidney  disease 20%
Medication
ACE  inhibitors/ARBs 96%
Beta-blockers  96%
Diuretics  80%
Spironolactone  52%
Digoxin  12%
ACE: angiotensin-converting enzyme; ARBs: angiotensin recep-
tor  blockers.
II, 13  in NYHA  class  III  and  one  in class  IV.  Mean  QRS  dura-
tion was  159±15  ms. All  patients  had  depressed  systolic
function with  severely  dilated  left cardiac  chambers  (mean
values: LVEF  29±5%,  LVESV  150±48  ml  and  LVEDV  207±60
ml). The  population  was  also  characterized  by  a  signiﬁcant
limitation of physical activity,  as  demonstrated  by  a  mean
peak VO2 of 18.4±5.0  ml/kg/min.  Mean  BNP  was  357±270
pg/ml. Most patients had multiple  comorbidities  and other
cardiovascular risk  factors,  notably  hypertension  (88%),  dys-
lipidemia  (80%),  diabetes  (32%),  obesity  (28%) and chronic
kidney disease  (20%).  All patients  were  under  optimal  medi-
cal treatment  (Table  2).
Controls
The  group  of  patients  were  compared  with  a control  group
of 15  age-matched  individuals  (age  58±8  years,  p=0.08).  In
the control  group,  eight  individuals  (53%)  were  female.  None
had a  history  of  cardiorespiratory  disease  or  dysautonomia
or was  taking  cardiovascular  medication.
Baroreﬂex  function
Baroreﬂex  function  was  signiﬁcantly  depressed  in  HF
patients compared  to controls.  Figure  1  summarizes  barore-
ﬂex function  in  HF patients  in  terms  of  NBR  and  BEI.  It shows
a signiﬁcant  reduction  of  NBR in HF  patients  both  during  the
basal period  (NBR  HF: 2.7±2.3  vs.  NBR controls:  3.9±1.6
events/min, p=0.017),  and  during  tilt  (NBR  HF: 2.7±2.8
vs. NBR controls:  5.0±2.5  events/min,  p=0.001).  Moreover,
HF patients  had  a  lower  BEI.  In basal  supine  position,
patients’  BEI  (34±14%)  was  signiﬁcantly  lower  (p=0.001)
than controls’  (51±15%).  Similar  results  were  found  for  the
orthostatic tilt  period  (BEI  HF: 31±12%  vs.  BEI  controls:
49±18%, p=0.001).  Interestingly,  no  differences  in barore-
ﬂex function  were  found during  recovery.
Association  between  baroreﬂex  function  and  other
clinical parameters  of heart  failure  severity
Of  all  the  parameters  assessed,  the following  were  selected
to better  characterize  HF  severity:  NYHA  functional  class,
QRS duration,  BNP, peak  VO2,  LVEF,  LVESV,  LVEDV  and  mitral
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Figure  1  Baroreﬂex  function  in candidates  for  cardiac  resynchronization  therapy  (green)  compared  to  healthy  controls  (blue),
measured  by  BEI and  NBR.  Heart  failure  patients  have  signiﬁcant  decreased  baroreﬂex  function.  Statistical  signiﬁcance  p<0.05
(Mann-Whitney  test).  BEI:  baroreﬂex  effectiveness  index;  NBR:  number  of  baroreﬂex  events  per  minute;  NS:  non-signiﬁcant.
Table  3  Correlation  between  baroreﬂex  function  and parameters  of  heart  failure  severity.
Baroreﬂex  function  NYHA  class  QRS  BNP  Peak  VO2 LVEF  LVESV  LVEDV  MR
Basal  BEI  Pearson’s  r -0.177  -0.19  -0.505  0.206  0.022  -0.221  -0.129 -0.111
p  0.431  0.398 0.033  0.428  0.926  0.428  0.646  0.65
Tilt BEI  Pearson’s  r -0.251  -0.287 -0.435  0.472  0.195  -0.541  -0.486 -0.021
p  0.248  0.184 0.038  0.048  0.385  0.031  0.056  0.931
Basal NBR  Pearson’s  r -0.059  -0.071 -0.314  0.256  0.193  -0.314  -0.243 -0.162
p  0.779  0.736 0.191  0.304  0.366  0.22  0.348  0.482
Tilt NBR  Pearson’s  r -0.265  -0.187 -0.537  0.428  0.354  -0.392  -0.331 0.007
p  0.201  0.371 0.018  0.077  0.09  0.12  0.195  0.977
BEI: baroreﬂex effectiveness index; BNP: brain-type natriuretic peptide; LVEDV: left ventricular end-diastolic volume; LVEF: left ven-
tricular ejection fraction; LVESV: left ventricular end-systolic volume; MR: mitral regurgitation; NBR: number of  baroreﬂex events per
minute; NYHA: New York Heart Association.
regurgitation  grade.  Table  3 shows  the calculated  correla-
tion coefﬁcients  between  the  above  variables  and NBR  or
BEI. During  tilt, a  lower  BEI  was  associated  with  higher  BNP
values (r=-0.435,  p=0.038),  higher  LVESV (r=-0.541,  p=0.031)
and  lower  peak  VO2 (r=0.472,  p=0.048)  (Figure  2). Fur-
thermore, there  was  a signiﬁcant  negative  correlation
between basal  BEI  and  BNP  (r=-0.505,  p=0.033),  as  well
as between  NBR during  tilt  and  BNP  (r=-0.517,  p=0.018),
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Figure  2  A  lower  BEI  was  associated  with  higher  BNP  values,  lower  peak  oxygen  consumption  and  increased  cardiac  volumes.  Statis-
tical  signiﬁcance  p<0.05  (Pearson’s  r linear  correlation  coefﬁcient).  BEI:  baroreﬂex  effectiveness  index;  BNP:  brain-type  natriuretic
peptide;  LVESV:  left  ventricular  end-systolic  volume;  VO2:  oxygen  consumption.
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Cluster 1 (BEI >25 %)
QRS  153 ms
LVESV   129 ml
BNP 146  pg /ml
Peak VO2 19.0  ml/kg/min
Cluster 2 (BEI  ≤25 %) 
QRS 167  ms
LVESV 189  ml
BNP 590  pg /ml
Peak VO2 16.2 ml/kg/min
Figure  3  Applying  a  cut-off  value  of  25%  for  BEI,  two  HF risk  clusters  were  obtained.  In  cluster  2  HF patients  who  present  low
baroreﬂex  function  have wider  QRS complexes,  higher  LVESV  and  BNP  values  and  reduced  functional  status  as  shown  by  peak  VO2.
This  is  therefore  the  patient  group  with  higher  HF clinical  risk  (K-means  clustering,  variables  expressed  as means).  BEI:  baroreﬂex
effectiveness  index;  BNP:  brain-type  natriuretic  peptide;  HF:  heart  failure;  LVESV:  left  ventricular  end-systolic  volume;  VO2: oxygen
consumption.
demonstrating  that  depressed  baroreﬂex  function  is  associ-
ated with  increased  BNP  values.  During  tilt,  the  associations
between BEI and  LVEDV  (r=-0.486,  p=0.056)  and  between
NBR and peak  VO2 were  non-signiﬁcant  (r=0.428,  p=0.077).
In  view  of the above  results,  BEI  during  tilt  was  used  to
stratify patients,  as  it was  the baroreﬂex  function  measure-
ment that  correlated  with  most  HF  severity  variables  (LVESV,
BNP and  peak  VO2). Applying  k-means  clustering,  a  cut-off
value of 25%  for  BEI  during  tilt  was  found  to  stratify  patients
into two  clusters  of  different  HF  severity  (Figure  3):  a low-
risk cluster  (BEI >25%)  with  QRS  duration  of 153  ms,  LVESV
129 ml,  BNP  146  pg/ml,  and  peak  VO2 19.0  ml/kg/min;  and  a
high-risk cluster  (BEI  ≤25%)  with  QRS  duration  167  ms,  LVESV
189 ml,  BNP  590  pg/ml,  and  peak  VO2 16.2 ml/kg/min.  These
clusters demonstrate  that  baroreﬂex  function  can  be  used
to better  stratify  HF  patients  who  are  candidates  for  CRT.
Discussion
Our  results  show  that  HF  patients  who  are candidates  for
CRT have  depressed  baroreﬂex  function.  This  is  in agree-
ment with  the  literature,  since  this population  consisted
of selected  HF  patients  and HF  is a  syndrome  classi-
cally characterized  by  compensatory  chronic  neurohormonal
hyperstimulation, with  hypersympathetic  activation  and
attenuation of  the  arterial  baroreﬂex.38,39 The  extent  of
the reduction  in  baroreﬂex  function  has  important  progno-
stic value  in  HF,  lower  values  of  baroreﬂex  sensitivity  being
associated with increases  in overall  mortality,  cardiovascu-
lar morbidity  and  mortality  and  HF hospital  admissions.24
Moreover,  BEI correlated  well  with  other  variables  of  HF
severity. Patients  with  lower  BEI  were those  with  increased
cardiac volumes  (LVESV  and LVEDV),  increased  BNP  and lower
functional capacity  (peak  VO2). BNP  and  peak  VO2 are  two
independent prognostic  markers  in HF.28,40 They  are widely
used in  risk  stratiﬁcation  of  HF patients,40 with  important
implications for  HF clinical  management  and  treatment,
including the utility  of  peak  VO2 in  stratifying  patients  for
cardiac transplantation.41 Besides  the importance  of barore-
ﬂex function  as  a prognostic  marker  in  HF,24 our  results  show
that it  correlates  well  with  other  risk  stratiﬁcation  varia-
bles including  BNP  and  peak  VO2,  supporting  the  idea  that
baroreﬂex function  itself  may  be  used in HF  risk  stratiﬁca-
tion. We  found  that  BEI during  tilt  could  be  used  to  divide
patients into  low-risk  and  high-risk  HF  groups  (Figure  3). In
our  study,  patients  with  BEI  lower  than  25%  had  more  severe
HF. We  suggest  further  studies  to  use  this cut-off  value  for
BEI in order  to  identify  patients  selected  for  CRT that have
more signiﬁcant  HF risk.
The  importance  of  the  baroreﬂex  in  CRT is  still  not  clear
as there  are  few  studies  on  this subject  in the  literature.
However, Braga  et  al. reported  one patient  who  fully  reco-
vered baroreﬂex  function  to  normal  values  three  months
after CRT.39 Moreover,  Gademan  et al. demonstrated  that
there was  an acute  increase  in baroreﬂex  sensitivity  and  HRV
after the implantation  of a biventricular  pacemaker25 and
that this  increase  was  predictive  of  the response  to  CRT.42
However,  in these  studies  baroreﬂex  function  was  assessed
only after the  implantation  of  a CRT  device,25,42 with  biven-
tricular pacing  switched  on and  off.  It  would be valuable
to assess  baroreﬂex  function  before and  after  CRT device
implantation to better  understand  the autonomic  impact  of
CRT on  cardiovascular  function.  Moreover,  the importance  of
a predictive  index  is  greater  when  assessed  before  implanta-
tion. Likewise,  there  are no  studies  demonstrating  that  the
increase in baroreﬂex  function  is sustained  chronically,  nor
if this  increase  correlates  with  cardiac  reverse  remodeling.
Further follow-up  studies  are necessary  to  better  answer  all
these questions.
Our methodological  approach  is  based on  the sequence
method,35 which  measures  baroreﬂex  function  through  a
non-invasive beat-to-beat  measurement  of HR  and SBP.
Although the studies  that  established  the prognostic
value of  the  baroreﬂex  used the  classic  method  for
measurement of  baroreﬂex  sensitivity  (the  phenylephrine
technique),24 there  is  signiﬁcant  evidence  that non-invasive
methods give  similar  results  to  those  obtained  through  the
phenylephrine technique  and  obviate  the  use  of  vasoactive
drugs.43,44 The  sequence  method  is  used to  calculate  BEI, a
new baroreﬂex  function index  that  measures  the effective-
ness with  which  the HR  responds  to  SBP  variations.36,37,45
BEI  is  less  liable  to  be  inﬂuenced  by ectopic  beats, which
were quite  frequent  in our  patients,  than  baroreﬂex  sensiti-
vity. Recently,  the assessment  of  baroreﬂex  function  through
non-invasive methods  by  the  use  of  provocative  maneuvers
has been  extended  to  different  clinical  entities  including
reﬂex syncope,30,37 atrial  ﬁbrillation,31 and  HF,25 in which  it
appears to  improve  speciﬁcity.  Our  work  is  the  ﬁrst  to  use
a tilt  test  in HF  patients  and  the  results  during  the ortho-
static period  provided  more  consistent  data  than  during  the
supine basal  period,  as  BEI  during tilt  correlated  with  more
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HF  severity  variables.  Our  approach  is  innovative  in the use
of  tilt  testing  in  patients  with  HF and our  results  show that
it is a  reproducible,  consistent  and well-tolerated  test.
The  size  of  our  study  group  (n=25)  is  the  main  limitation
of this  work.  Moreover,  the  control  group  also  presents  some
limitations, as  it  was  age-matched  but  not gender-matched.
Furthermore, the fact that  all  patients  were under  optimal
medical treatment  may  also  be  considered  a  limitation  to a
work that  aims to assess  basal  baroreﬂex  function,  as  96%  of
patients were  taking  a  beta-blocking  agent.  Nevertheless,  La
Rovere  et  al.  have  recently  shown  in  a prospective  study  that
there are  no  signiﬁcant  differences  in baroreﬂex  sensitivity
between HF  patients  treated  with  beta-blockers  and  those
that are  not.46
Our  work  shows  the importance  of baroreﬂex  assessment
in risk  stratiﬁcation  of  HF patients  who  are candidates  for
CRT. In the  future,  prospective  studies  with  at  least  a  six-
month post-CRT  follow-up  are needed  in  order  to  demons-
trate the  existence  of  autonomic  remodeling  associated  with
CRT and  to  assess  whether  baroreﬂex  measurements  have
predictive value  concerning  response  to  CRT.
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